VivoSeq
Other

Interleukin

0

Pipeline Programs↗

5

Active Trials↗

6

Companies Involved↗

Interleukin is an early-stage landscape with 0 programs across 6 companies. The most active players are Novartis, Jecho Biopharmaceuticals Co., Ltd., Beijing Northland Biotech. Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalJ

Jecho Biopharmaceuticals Co., Ltd.

0 programs

PreclinicalB

Beijing Northland Biotech. Co., Ltd.

0 programs

PreclinicalB

BZL Biologics

0 programs

PreclinicalVertex Pharmaceuticals logo

Vertex Pharmaceuticals

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

63

clinical trials

Completed47 · 75%
Terminated6 · 10%
Unknown status4 · 6%
Recruiting3 · 5%
Not yet recruiting1 · 2%
Withdrawn1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

63 trials

Neutralizing Interleukin (IL)-6
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT07493317·60 enrolled
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT06920199·18 enrolled
Interleukin23 in Systemic Lupus
Recruiting·SSohag University·N/A·NCT06713187·90 enrolled
Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders
Not yet recruiting·JJecho Biopharmaceuticals Co., Ltd.·Phase 1·NCT07443228·52 enrolled
Interleukin-15 to Promote Post-ART Control of HIV
Enrolling by invitation·MMichael Peluso, MD·Phase 2·NCT07145164·20 enrolled
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001005·30 enrolled
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
Completed·RRoswell Park Cancer Institute·Phase 1·NCT00058045·1 enrolled
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001357·80 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Completed·National Cancer Institute (NCI)·Phase 1·NCT00004074·15 enrolled
A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11
Completed·BBeijing Northland Biotech. Co., Ltd.·Phase 3·NCT01663441·62 enrolled
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
Completed·—·Phase 2·NCT02340676·25 enrolled
Anti-Interleukin-1 in Diabetes Action
Completed·SSteno Diabetes Center Copenhagen·Phase 2/3·NCT00711503·69 enrolled
Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120185·130 enrolled
A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia
Completed·Novartis logoNovartis·Phase 1·NCT00002258
Pregabalin on Interleukin-6 Levels in Living Donor Kidney
Completed·FFederal University of São Paulo·Phase 2·NCT01529190·40 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)